PrecisionLife Market Research Report
Company Overview
Name: PrecisionLife
Mission: Driving precision medicine into chronic diseases to create better, more personalized treatment options for patients with unmet medical needs.
Founded: No information is available.
Founders: No information is available.
Key People:
- Dr. Steve Gardner, Chief Executive Officer
- Ray Pawlicki, Executive Chairman
- Dr. Véronique Bouchet, Chief Medical Officer
- Rowan Gardner, Chief Business & Investment Officer
- Gert Møller, Ph.D., Chief Analytics Officer
- Adrian Andrews, Interim Chief Financial Officer
- Mark Strivens, Chief Technology Officer
- Sandy Hogg, Ph.D., SVP Alliance Management
- Marcin Pawlowski, Ph.D., Chief Data Science Officer
- Colin Stubberfield, Ph.D., SVP Drug Discovery
- Sayoni Das, Ph.D., SVP Bioinformatics
- Simon Beaulah, SVP Healthcare & Head of US
- Noah Konig, Marketing Director
- Gerald Dunstan, Ph.D., SVP Corporate Development
Headquarters: No information is available.
Number of Employees: No information is available.
Revenue: No information is available.
Known For: PrecisionLife is known for generating the deepest insights into complex chronic diseases, accelerating better drug development, and personalizing healthcare to meet unmet medical needs.
Products
PrecisionLife focuses on offering products and services that leverage deep insights into disease biology, particularly for chronic diseases. They use their combinatorial analytics platform to:
Precision Biopharma
- Novel Drug Targets: Discover and validate new drug targets, particularly for chronic diseases.
- Indication Extension Opportunities: Reposition existing drugs for new indications.
- Enrichment of Clinical Trials: Identify patient responders and enrich clinical trials to ensure better outcomes.
Precision Healthcare
- Combinatorial Risk Scores: Create personalized risk models for better population health management.
- Clinical Decision Support: Tools to select effective, personalized treatments and care pathways.
- Precision Diagnostics: Tools for early, accurate diagnosis of chronic diseases.
Key features of their products include:
- Patient Stratification: Unrivaled ability to identify subgroups of patients with similar disease drivers and treatment responses.
- High-Resolution Insights: Deep biological understanding of disease mechanisms tailored to patient subgroups.
Recent Developments
Partnerships
- Metrodora Institute: Joint efforts to accelerate the diagnosis and treatment of Long COVID, ME/CFS, and other chronic conditions.
- Absci: Strategic R&D partnership to jointly develop an AI-enabled drug pipeline.
- MetX Study Participation: Sharing first insights with participants in ME/CFS and Long COVID clinical trials.
Awards and Recognitions
- Innovation Showcase Award: Won at CNS Summit highlighting their innovative contributions to precision medicine.
Product Launches and Features
- AI-Led Innovation Engine: Launched to improve drug discovery and precision medicine capabilities.
- DiseaseBank™: Continues to run chronic disease datasets through their platform to uncover new insights consistently.
New Alliances
- Strategic R&D Partnerships: Expansion with major industry players like Ono Pharmaceutical, Sosei Heptares, and others for discovering novel CNS targets and leveraging GPCR potentials.
Conclusion
PrecisionLife is a leader in the precision medicine landscape with a focus on bringing personalized treatment solutions to chronic disease patients. Through their proprietary analytics and strategic partnerships, they continue to push the boundaries in drug discovery, clinical trial innovation, and precision healthcare delivery.
